Democratic leaders of the House Energy and Commerce Committee today released findings from their investigation of 14 companies that sell or help consumers sign up for short-term, limited duration health plans.

Among other findings, they said all eight plans they investigated deny claims for pre-existing conditions; that most of them “systematically exclude coverage for most major medical conditions resulting from pre-existing conditions”; and that the average broker commission for the plans they investigated was 23% compared with 2% for Affordable Care Act-compliant plans in 2018.

They also said that less than half of the premium dollars collected from consumers are spent on medical care, unlike ACA-compliant individual market plans, which are required to spend at least 80% of premium dollars on health care; and that enrollment in the plans rose 27% in 2019 to about 3 million consumers.

In addition, they said consumers who purchase this type of health plan are more likely to have substantial out-of-pocket medical costs due to the lack of coverage provided by these companies.

Related News Articles

Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Headline
The American Medical Association Dec. 16 released its latest annual report on health insurance competition, finding that 97% of commercial markets were highly…
Headline
Approximately 950,000 consumers who currently do not have health insurance coverage through the federally facilitated Health Insurance Marketplace have signed…
Headline
The Senate today failed to pass legislation to address health care affordability. The chamber first voted on a Republican-backed bill that failed by a 51-…
Headline
The AHA Dec. 9 expressed support for the Critical Access for Veterans Care Act (S. 1868), legislation that would expand veteran access to critical access…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…